Skip to main content

High-Sensitivity Troponin Assay From Ortho Clinical Diagnostics CE Marked

NEW YORK (360Dx) – Ortho Clinical Diagnostics said today that its next-generation Vitros High Sensitivity Troponin I assay has been CE marked.

The test can be used to rapidly and accurately identify patients suffering from heart attacks, and to help identify low-risk patients who may be safely discharged, reducing both healthcare costs and resource burden on hospitals, Ortho said.

The Vitros High Sensitivity Troponin I assay can run on the company's Vitros XT 7600 Integrated System, the Vitros ECi/ECiQ Immunodiagnostic Systems, the Vitros 3600 Immunodiagnostic System, and the Vitors 5600 Integrated System.

Heidi Casaletto, head of portfolio strategy and marketing at Ortho said in a statement "Improved analytical performance complies with the International Federation of Clinical Chemistry and Laboratory Medicine definition of high sensitivity, enabling use with rapid rule-in/rule-out diagnostic protocols and allowing hospitals to more quickly diagnose and treat patients."